Advertisement
Terms of the agreement were not disclosed. The transaction is subject tocustomary clearances, including the Hart-Scott-Rodino Antitrust ImprovementsAct and similar regulations in other countries.
Advertisement
"Ethicon Endo-Surgery and SurgRx share a commitment to innovation for thesurgeons and patients who depend on our products," said Karen Licitra, CompanyGroup Chairman and Worldwide Franchise Chairman, Ethicon Endo-Surgery."Together, the combination of HARMONIC(R) and EnSeal(R) technologies willposition us to better address many different procedure needs."
"The acquisition has the potential to expand the global availability ofthe EnSeal(R) product line," said Rodney Perkins M.D., Chairman, Board ofDirectors, SurgRx. Dave Clapper, President & CEO, SurgRx added, "We arelooking forward to joining forces with Ethicon Endo-Surgery to offer thesecomplementary technologies to even more patients worldwide."SurgRx was founded in 2002 and is located in Redwood City, Calif. TheEnSeal(R) family of devices combines high compression and controlled energydelivery to quickly create strong vessel seals. The EnSeal(R) device, clearedby the FDA in 2003, is capable of sealing vessels up to 7mm in diameter.
About Ethicon Endo-Surgery
Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, develops andmarkets advanced medical devices for minimally invasive and open surgicalprocedures, focusing on procedure-enabling devices for the interventionaldiagnosis and treatment of conditions in general and bariatric surgery, aswell as gastrointestinal health, gynecology and surgical oncology. Moreinformation can be found at www.ethiconendo.com.
(This press release contains "forward-looking statements" as defined inthe Private Securities Litigation Reform Act of 1995. These statements arebased on current expectations of future events. If underlying assumptionsprove inaccurate or unknown risks or uncertainties materialize, actual resultscould vary materially from Ethicon Endo-Surgery's expectations andprojections. Risks and uncertainties include the satisfaction of closingconditions for the acquisition, including receipt of regulatory approvals forthe transaction, and the possibility that the transaction will not becompleted; general industry conditions and competition; economic conditions,such as interest rate and currency exchange rate fluctuations; technologicaladvances and patents attained by competitors; challenges inherent in newproduct development, including obtaining regulatory approvals; domestic andforeign health care reforms and governmental laws and regulations; and trendstoward health care cost containment. A further list and description of theserisks, uncertainties and other factors can be found in Exhibit 99 of Johnson &Johnson's Annual Report on Form 10-K for the fiscal year ended December 30,2007. Copies of this Form 10-K, as well as subsequent filings, are availableonline at www.sec.gov, www.jnj.com or on request from Johnson & Johnson.Ethicon Endo-Surgery does not undertake to update any forward-lookingstatements as a result of new information or future events or developments.)HARMONIC is a trademark of Ethicon Endo-Surgery, Inc. EnSeal is a trademark of SurgRx, Inc.
SOURCE Ethicon Endo-Surgery, Inc.
